Clinical Trial Update: PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma [Phase 2]

View source ↗

Summary

This document describes a Phase 2, single-arm neoadjuvant trial of cemiplimab, fianlimab, and ipilimumab in surgically resectable melanoma. The study status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Fianlimab (fianlimab)
• Libtayo (cemiplimab)
• Yervoy (ipilimumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Melanoma | Phase 2 | Status: NOT_YET_RECRUITING